Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

FDA Places New Clinical Hold On RGX-121 for Hunter Syndrome

25 August 2026 · By · Wire by Fusion42

Published

25 August 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at cgtlive.com →

◆ Verified

Fusion42 · 26 August 2026 · Fusion42 review

The FDA has placed a new clinical hold on REGENXBIO's RGX-121 gene therapy for Hunter syndrome following detection of asymptomatic spine MRI abnormalities in five trial participants, marking the second regulatory setback for the therapy in 2026.

This Wire brief sits within Fusion42's coverage of Biotech, and 3 sources have reported it between 24 Aug 2026 and 31 Aug 2026.

◆ ◆ The Wire takeaway

You face a tougher regulatory environment for Hunter syndrome gene therapies after recurring FDA holds. Accelerate alternative programs or pivot clinical efforts to maintain momentum amid delays.

◆ Coverage

3 sources · first reported 24 Aug 2026 · latest 31 Aug 2026

◆ Related on Wire

◆ Topics

Biotechgene-therapyclinical-holdregulatory-setbackhunter-syndromeFDA